The Effect Of Fuzhengyiliu Therapy On Living Quality, PSA And Bone Metastasis Of Prostate Cancer With Bone Metastasis In D2 Period

Background Prostate cancer is familiar to male. It is in the primary inincidence in male tumour in America and the third in Chinese urological tumour.In clinic, most of prostate cancer is in terminal period when diagnosed andit is difficult to cure with modern medical. Incretion therapy is effectualat first, but after about 14 to 30 months, almost progresses to hormonerefractory prostate cancer (HRPC). The living quality of HRPC is bad, themedian survival time is 12 to 20 months. In present the medical therapy cannot affirmatively prolong the living time, in contrary, some therapy stilldepress the living quality. Research inside and outside in TCM bring usforeground in therapy of prostate cancer. Years of research in prostate cancer,surgical urology in Guangdong hospital of TCM has researched into pathogeny,pathology,symptom category of terminal prostate cancer and treated terminalprostate cancer with Fuzhengyiliu therapy, which showed good foreground inimproving the living quality and prolonging the living time.Objective Based on the research in pathogeny,pathology,symptom categoryof prostate cancer in D period, discuss the feasibility of constituting therapyintegrated traditional Chinese medicine and western medicine for prostatecancer in D2 Period with bone metastasis which in the light of the theory ofChinese medicine and the modern experimental research fruits in herbs. UseQLQ-C30 table in clinical research of prostate cancer which is for researchin living quality, taking living quality,PSA,the amount of bone metastasisas the clinical research target, discuss the clinical curative effect ofFuzhengyiliu therapy on prostate cancer in D2 Period with bone metastasis.Method Prospective study and referring to control principle, 144available cases of inpatient or outpatient in Guangdong hospital of TCM fromSep. 2004 to Mar. 2007 were separated into two groups, 109 in the remedy group and 35 in the control group. The remedy group was treated with Fuzhengyiliutherapy and the control group was treated with modern medical therapy. Thetreat period was 9 months. Collect information of Karnofsky table,weight,QLQ-C30 table,I—PSS table,ache classification table of WHO,table forresearch in symptom category of prostate cancer in D period,PSA,bloodtestosterone,ECT of systemic bones,analysis of blood corpuscle, etc..Result The remedy group is obviously better than the control group inincreasing weight, improving the scale of Karnofsky table, alleviatingsymptoms such as tiredness,pain,insomnia,appetite losing,pressingbreach,constipation,diarrhea, improving the emotion function and healthcondition in whole; improving the symptom of lower urethra; reducing theincidence rate of the symptom such as tiredness and fatigue, insomnia,desudation, poor appetite, difficult in urethra, pain in waist and knee, etc.,reducing the amount of PSA and bone metastasis(P＜0.05), enhancing the amountof blood corpuscle such as WBC,HGB,PLT in circulation.Conclusion Fuzhengyiliu therapy can improve the living quality ofprostate cancer patients in D2 Period with Bone Metastasis, which is betterthan single modern therapy. In certain period, Fuzhengyiliu therapy reducesTPSA and the amount of bone metastasis, delay the progress of prostate cancerin D2 Period, which is also better than single modern therapy.